1. The REFLO-STEMI (REperfusion Facilitated by LOcal adjunctive therapy in ST-Elevation Myocardial Infarction) trial: a randomised controlled trial comparing intracoronary administration of adenosine or sodium nitroprusside with control for attenuation of microvascular obstruction during primary percutaneous coronary intervention
    Sheraz A Nazir et al, 2016, Efficacy Mech Eval CrossRef
  2. Candesartan ameliorates acute myocardial infarction in rats through inducible nitric oxide synthase, nuclear factor-κB, monocyte chemoattractant protein-1, activator protein-1 and restoration of heat shock protein 72
    XUEFENG LIN et al, 2015 CrossRef
  3. Effects of different routes of tirofiban injection on the left ventricular function and prognosis of patients with myocardial infarction treated with percutaneous coronary intervention
    CUIHUA ZHAO et al, 2015 CrossRef
  4. Intracoronary administration of anisodamine and nicorandil in individuals undergoing primary percutaneous coronary intervention for acute inferior myocardial infarction: A randomized factorial trial
    CHUNHONG CHEN et al, 2015 CrossRef
  5. Effect of intracoronary agents on the no-reflow phenomenon during primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: a network meta-analysis
    Xiaowei Niu et al, 2018, BMC Cardiovasc Disord CrossRef
  6. Management of No-Reflow Phenomenon in the Catheterization Laboratory
    Shereif H. Rezkalla et al, 2017, JACC: Cardiovascular Interventions CrossRef
  7. Long-term clinical outcomes of transient and persistent no-reflow following percutaneous coronary intervention (PCI): a multicentre Australian registry
    Stavroula Papapostolou et al, 2018, EuroIntervention CrossRef
  8. null
    Francesco Fracassi et al, 2018 CrossRef
  9. null
    Thomas Stiermaier et al, 2018 CrossRef
  10. Combined Primary PCI with Multiple Thrombus Burden Reduction Therapy Improved Cardiac Function in Patients with Acute Anterior Myocardial Infarction
    Kun Wang et al, 2019, Int. Heart J. CrossRef
  11. Effect of Intracoronary Nitroprusside in Preventing No Reflow Phenomenon during Primary Percutaneous Coronary Intervention: A Meta-Analysis
    SHIJIE ZHAO et al, 2014, J. Int. Cardiol CrossRef
  12. Pathophysiology, Diagnosis, and Management of the No-Reflow Phenomenon
    Joseph Allencherril et al, 2019, Cardiovasc Drugs Ther CrossRef
  13. The REFLO-STEMI trial comparing intracoronary adenosine, sodium nitroprusside and standard therapy for the attenuation of infarct size and microvascular obstruction during primary percutaneous coronary intervention: study protocol for a randomised controlled trial
    Sheraz A Nazir et al, 2014, Trials CrossRef
  14. Coronary no-reflow in the modern era: a review of advances in diagnostic techniques and contemporary management
    Jathinder Kumar et al, 2019, Expert Review of Cardiovascular Therapy CrossRef
  15. Strategies to attenuate micro-vascular obstruction during P-PCI: the randomized reperfusion facilitated by local adjunctive therapy in ST-elevation myocardial infarction trial
    Sheraz A. Nazir et al, 2016, Eur Heart J CrossRef
  16. Efficacy and Safety of Local Intracoronary Drug Delivery in Treatment of No-Reflow Phenomenon: A Pilot Study
    Tamer Abu Arab et al, 2016 CrossRef
  17. Efficacy and safety of intracoronary epinephrine versus conventional treatments alone in STEMI patients with refractory coronary no‐reflow during primary PCI : The RESTORE observational study
    Eliano P. Navarese et al, 2020, Catheter Cardiovasc Interv CrossRef
  18. Primary angioplasty after distal intracoronary infusion of nicorandil solution mixed with contrast media
    Udaya Prashant Ponangi, 2020, BMJ Case Rep CrossRef
  19. Pathophysiology, Diagnosis, and Management of Coronary No-Reflow Phenomenon
    Gagan Kaur et al, 2021, Int J Angiol CrossRef
  20. Sodium nitroprusside injection immediately before balloon inflation during percutaneous coronary intervention
    Yan Yu et al, 2021, WJCC CrossRef
  21. Pathophysiology, Diagnosis, and Management of Coronary No-Reflow Phenomenon
    Gagan Kaur et al, 2022, Int J Angiol CrossRef
  22. Intracoronary epinephrine and verapamil in the refractory no-reflow phenomenon in patients with acute myocardial infarction
    S. V. Dil et al, 2022, Cardiovasc Ther Prev CrossRef
  23. Prophylactic use of intracoronary sodium nitroprusside decreases incidence of no reflow after primary angioplasty in acute myocardial infarction
    Sujith Kumar et al, 2021, KERALA HEART J CrossRef
  24. Intracoronary Administration of Drugs in Clinical Practice
    Sergii V. Salo et al, 2022, ujcvs CrossRef